Write a 500- to 1000-word paper addressing the following: Summarize the research study. Identify possible ethical concerns related to the research process. Explain how these ethical issues or concerns can influence the research outcomes. Define validity as it relates to the research study. Hint: Review previous learning activities for key validity concepts, including internal and external validity and associated threats to validity. Discuss the importance of research design validity and how research bias can impact the validity. Hint: Review how research design validity and instrumentation validity are different concepts. Discuss how stakeholders can externally influence healthcare research. Include possible ethical concerns. Article has been uploaded
US Health Care Clinicians’ Knowledge, Attitudes,
and Practices Regarding Human Papillomavirus
Vaccination: A Qualitative Systematic Review
Brittany L. Rosen, PhD, CHES; Allie Shepard, MA, CHES; Jessica A. Kahn, MD, MPH
From the University of Cincinnati, School of Human Services (Dr Rosen and Ms Shepard), Cincinnati Children’s Hospital Medical Center,
Division of Adolescent and Transition Medicine (Dr Kahn), and University of Cincinnati, College of Medicine (Dr Kahn), Cincinnati, Ohio
Dr Kahn chaired the review committee for a grant to the Society for Adolescent Health and Medicine evaluating public health demonstration
project proposals to improve adolescent vaccination; grant funding for this program was from Merck,Inc. Dr Kahn also cochaired 2 human
papillomavirus vaccine clinical trials in HIV-infected individuals, which were funded by the National Institutes of Health (grant numbers U01 HD
040533 [NICHD], U01 HD 040474 [NICHD], UM1CA121974 [NCI], and U01 CA121947 [NCI]) but for which Merck & Co, Inc provided vaccine
and immunogenicity titers. The remaining authors have no conflicts of interest to disclose.
Address correspondence to Brittany L. Rosen, PhD, CHES, University of Cincinnati, School of Human Services, PO Box 210068, Cincinnati,
Ohio 45221 (e-mail: brittany.rosen@uc.edu).
Received for publication April 16, 2017; accepted October 21, 2017.
ABSTRACT
Clinicians’ recommendation for the human papillomavirus
(HPV) vaccine appears to be an important driver of parental
decisions about vaccination. Our aim was to synthesize the
best available evidence exploring the perceptions and experiences
regarding HPV vaccination, from the perspective of the
US clinician. We conducted a comprehensive literature search
of Academic Search Complete, CINAHL Plus, Communication
& Mass Media Complete, Consumer Health Complete
(EBSCOhost), ERIC, Health and Psychosocial Instruments,
MEDLINE with full text, and PsycINFO databases. We identified
60 eligible articles: 48 quantitative and 12 qualitative. We
extracted the following information: study purpose, use of
theory, location, inclusion criteria, and health care provider
classification. Results were organized into 5 categories: 1) clinicians’
knowledge and beliefs about HPVand the HPV vaccine,
2) clinicians’ attitudes and beliefs about recommending HPV
vaccines, 3) clinicians’ intention to recommend HPV vaccines,
4) clinicians’ professional practices regarding HPV vaccination,
and 5) patient HPV vaccination rates. Although clinicians were
generally supportive of HPV vaccination, there was a discrepancy
between clinicians’ intentions, recommendation practices,
and patient vaccination rates. Studies reported that clinicians
tended not to provide strong, consistent recommendations,
and were more likely to recommend HPV vaccines to girls
versus boys and to older versus younger adolescents. Analyses
revealed a number of facilitating factors and barriers to HPV
vaccination at the clinician, parent/patient, and systems levels,
including clinician knowledge, clinician beliefs, and office
procedures that promote vaccination. This review provides an
evidence base for multilevel interventions to improve clinician
HPV vaccine recommendations and vaccination rates.
KEYWORDS: attitudes; health knowledge; nurses; human
papillomavirus vaccines; physicians; pediatrics
ACADEMIC PEDIATRICS 2018;18:S53–S65
HUMAN PAPILLOMAVIRUS (HPV) is the most common
sexually transmitted infection, with a prevalence rate of
43% among US adults.1 HPV might have serious health
consequences for men as well as women, including anogenital
cancers (cervical, vaginal, vulvar, penile, and
anal), oropharyngeal cancers, and anogenital warts.2 To
prevent the potential health consequences, 3 HPV vaccines
(2-valent, 4-valent, and 9-valent) have been licensed in the
United States. Data from clinical trials have shown that
these vaccines are almost 100% effective in preventing
infection and precancers caused by the targeted HPV types,
if given before HPV acquisition,3–8 and that the 4-valent
and 9-valent vaccines are highly effective in preventing
anogenital warts.5–7 HPV vaccine introduction in realworld
settings has led to dramatic declines in vaccinetype
HPV prevalence and anogenital warts.9–11 Despite
the potential for HPV vaccines to decrease morbidity and
mortality associated with these outcomes, vaccine uptake
remains below the Healthy People 2020 objective of 80%
coverage. In the United States during 2014 to 2015, only
43% of 13- to 17-year-old girls and 32% of 13- to
17-year-old boys had completed the HPV vaccine series.12
Health care clinicians play a key role in HPV vaccine
uptake, and clinicians’ recommendation for the vaccine
appears to be an important driver of parental decisions to
vaccinate their child.13 However, research has shown that
there are considerable missed clinical opportunities to
recommend and administer the HPV vaccine. Furthermore,
higher quality and strength of HPV vaccine recommendations
predict a higher odds of initiation and vaccine series
completion.14 However, the strength and consistency of
clinician recommendations for HPV vaccine is lower
than for other adolescent vaccines: in 1 study, two-thirds
of 11- and 12-year-old girls did not receive an HPV vaccine
ACADEMIC PEDIATRICS
Copyright ª 2017 by Academic Pediatric Association S53
Volume 18, Number 2S
March 2018
at a visit during which they received at least 1 other vaccine.
15 Missed opportunities to vaccinate have been cited
as the primary reason the United States has not achieved
high HPV vaccination rates.16
Because of relatively low rates of HPV vaccination, the
importance of clinicians’ vaccine recommendation, and
missed opportunities to vaccinate, understanding health
care clinicians’ knowledge, attitudes, and professional
practices regarding the HPV vaccine is important for developing
evidence-based interventions to improve the consistency
and strength of HPV vaccine recommendations.
Therefore, our aim was to synthesize the best available
evidence on the perceptions and experiences regarding
HPV vaccination, from the perspective of the US clinician.
METHODS
For the purpose of this review, health care clinician was
defined as an individual qualified to deliver health care
services (eg, physicians, clinical nurses, school nurses) to
patients within the recommended age group for vaccination
(9–26 years of age). A comprehensive literature search
of Academic Search Complete, CINAHL Plus with Full
Text, Communication &Mass Media Complete, Consumer
Health Complete (EBSCOhost), ERIC, Health and Psychosocial
Instruments, MEDLINE with Full Text, and
PsycINFO databases was conducted, using variations and
Boolean connectors with the following terms: human
papillomavirus, vaccine, immunization, vaccine, health
care provider, perception, and practice. In addition to the
electronic searches, each article was scanned in Scopus
for potentially missed citations that cited the article
produced in the initial search.
The following criteria were used for inclusion of articles
in this review: 1) original empirical reports (including
quantitative and qualitative studies) published in a peerreviewed,
English language journal, 2) studies conducted
in the United States, 3) data collection took place after the
US Food and Drug Administration approval of the vaccine
(2006), and 4) methodology included examination of the
knowledge, perceptions, and/or professional practices of
health care professionals regarding the HPV vaccine. Articles
were excluded if they were commentaries, editorials,
or personal perspectives. All articles published through
August 2016 were retrieved (the date in which searching
began). Information concerning the time frame the data
were collected, purpose of the study, use of theory, location
of study, inclusion criteria, classification of health care provider,
study design, and sample size were extracted from
eligible studies. Additionally, information about clinicians’
knowledge about, perceptions of, and practices regarding
the HPV vaccine were extracted. Data were abstracted and
entered into a database by Dr Rosen and Ms Shepard. Dr
Rosen independently abstracted the data from the first 35
articles (all articles published from 2008 to 2014), and Ms
Shepard independently abstracted the data from the remaining
22 articles (published from 2015 to 2016). Dr Rosen and
Ms Shepard also identified themes and subthemes through
content analysis on the basis of the data in the articles. Dr
Kahn conducted an independent review of the themes and
subthemes providing validation of data classification, as
well as reviewing the abstracted data to ensure the data
were aligned with the themes and subthemes. Any discrepancies
in classification were resolved through discussion
between Dr Rosen, Ms Shepard, and Dr Kahn.
RESULTS
Sixty articles were identified for this review, including
48 quantitative and 12 qualitative studies. The range of
publication dates included 2008 through 2016: most
studies (n ¼ 15) were published in 2016, and most of these
(n ¼ 13) were conducted in 2010. Five studies did not
provide information about the geographic area where the
research was conducted. In 25 studies, data were derived
from a national data set. The remainder of the studies
reported data collected from states in the Northeast
(n ¼ 6), Midwest (n ¼ 10), South (n ¼ 12), and West
(n ¼ 2) as defined by the US Census Bureau. Participants
in the studies included pediatricians (n ¼ 29), family practitioners
(n¼26), obstetricians and gynecologists (n¼12),
physicians not otherwise classified (n ¼ 13), nurse practitioners
(n ¼ 13), general practitioners (n ¼ 8), internal
medicine physicians (n ¼ 7), registered nurses (n ¼ 6),
physician assistants (n ¼ 5), preventive medicine physicians
(n ¼ 2), and school nurses (n ¼ 2). Of the 48 quantitative
studies, the sample size ranged from 50 to 2119
clinician participants. The sample size in the 12 qualitative
studies ranged from 8 to 61 participants. Twelve of the 48
quantitative studies explicitly stated using a theory or
model to collect and/or analyze data, including theory of
planned behavior (n ¼ 5), competing demands model
(n ¼ 4), diffusion of innovations (n ¼ 3), health belief
model (n ¼ 2), shared decision-making framework
(n ¼ 1), and transtheoretical model (n ¼ 1). Four of the
studies reported using more than 1 theory or model.
Analytic methods included grounded theory/constant
comparison methods in 6 of the qualitative studies. Study
characteristics are shown in Table 1.
We organized study results into the following primary
categories: 1) clinicians’ knowledge and beliefs about
HPV and the HPV vaccine, 2) clinicians’ attitudes and
beliefs about recommending HPV vaccines, 3) clinicians’
intention to recommend HPV vaccines, 4) clinicians’
professional practices regarding HPV vaccination, and 5)
patient HPV vaccination rates. For the last 3 categories
(intention to recommend HPV vaccines, professional practices
regarding HPV vaccination, patient HPV vaccination
rates) we also included factors associated with each of
these outcomes if the data were available. Within each
category, themes were identified and subthemes classified
through content analysis. For results that are summarized
in the following sections and also presented in tables,
citations are included in each table.
S54 ROSEN ET AL ACADEMIC PEDIATRICS
Table 1. Study Characteristics
Reference Study Design N Study Population
Measure
HPV and Vaccine
Knowledge
Recommending
Attitudes
Intentions to
Recommend
Professional
Practice
Patient
Vaccine Rates
Feemster et al17 Quantitative, cross-sectional 101 Pediatrics
Ishibashi et al18 Quantitative, cross-sectional 373 Pediatrics
Ishibashi et al19 Quantitative, cross-sectional 373 Pediatrics
Jensen et al20 Quantitative, cross-sectional 204 Pediatrics, NP, FM, and gynecology
Kahn et al21 Quantitative, cross-sectional 1122 Pediatrics, OBGYN, FM, IM, and
other
Askelson et al22 Quantitative, cross-sectional 207 Physicians (FM, IM, and pediatrics)
Barnack et al23 Quantitative, cross-sectional 100 Pediatrics, OBGYN, FM, IM, and
other
Cook et al24 Quantitative, cross-sectional 550,048 Girls aged 9–20 years*
Daley et al25 Quantitative, cross-sectional 680 Pediatrics and FM
Ko et al26 Quantitative, cross-sectional 424 Pediatrics, OBGYN, and IM
McCave27 Quantitative, cross-sectional 227 Pediatrics, physicians, OBGYN,
PA, and NP
Weiss et al28 Quantitative, cross-sectional 1094 Pediatrics and FM
Hughes et al29 Qualitative, individual interviews 20 Physicians
Roberto et al30 Quantitative, cross-sectional 406 Pediatrics
Tan et al31 Quantitative, cross-sectional 733 OBGYN, FM, and IM
Vadaparampil et al32 Quantitative, cross-sectional 1013 Pediatrics, OBGYN, and FM
Young et al33 Quantitative, cross-sectional 385 OBGYN and FM
Zimet et al34 Quantitative, cross-sectional 271 OBGYN, FM, and IM
Javanbakht et al35 Qualitative, in-person interviews 21 Physicians, PA, medical assistants,
and case managers
Perkins and Clark36 Qualitative, in-depth interviews 34 Physicians and NP
Aragones et al37 Quantitative, cross-sectional 93 Pediatrics, FM, and IM
Head et al38 Qualitative, semistructured
interviews
8 Physicians, NP, and licensed
practical nurses
Holder et al39 Quantitative, cross-sectional 254 Doctors of medicine, pediatrics,
adolescent medicine subboarded,
RN, certified NP
Malo et al40 Quantitative, cross-sectional 433 Pediatrics, OBGYN, FM, IM, and
preventive medicine
Perkins et al41 Quantitative, cross-sectional 366 OBGYN
Perkins and Clark42 Qualitative, semistructured
interviews
34 Pediatrics, FM, and NP
Post et al43 Quantitative, cross-sectional 112 Recent graduates from FM
residencies
Hill and Okugo44 Quantitative, cross-sectional 50 Emergency medicine physicians
and residents
Malo et al45 Quantitative, cross-sectional 728 FM and pediatrics
McRee et al46 Quantitative, cross-sectional 575 Physicians and NP
Roland et al47 Quantitative, cross-sectional 98 Physicians, NP, certified nurse
midwives, and physicians
(Continued )
ACADEMIC PEDIATRICS CLINICIANS’ KNOWLEDGE, ATTITUDES, AND PRACTICES REGARDING HPV VACCINATION S55
Table 1. Continued
Reference Study Design N Study Population
Measure
HPV and Vaccine
Knowledge
Recommending
Attitudes
Intentions to
Recommend
Professional
Practice
Patient
Vaccine Rates
Vadaparampil et al48 Quantitative, 2 cross-sectional
surveys
1013 (2009),
928 (2011)
FM, pediatrics, and OBGYN
Alexander et al49 Qualitative, semistructured
interviews
20 Pediatrics (IM and adolescent)
Berkowitz et al50 Quantitative, cross-sectional 1753 FM, IM, NP, pediatrics, and
OBGYN
Gilkey et al51 Quantitative, cross-sectional 1022 Pediatrics and FM
Gilkey et al52 Quantitative, cross-sectional 1022 Pediatrics and FM
Katz and Paskett53 Qualitative, cross-sectional Not stated Physicians, nurses, and medical
assistants
Rahman et al54 Quantitative, cross-sectional 23,564 Unspecified medical providers
Rosen et al55 Quantitative, cross-sectional 413 School nurses
Suryadevara et al56 Quantitative, cross-sectional 680 Nurse, midlevel provider, and
physician
Allison et al57 Quantitative, cross-sectional 582 Pediatrics and FM
Askelson et al58 Quantitative, cross-sectional 127 Clinic managers
Berkowitz et al59 Quantitative, cross-sectional 2119 OBGYN and primary care providers
(IM, FM, and midlevel providers)
Dempsey et al60 Quantitative, cross-sectional 356 Parents of adolescent children‡
Gilkey et al14 Quantitative, cross-sectional 1495 Parents of 11- to 17-year-old
adolescents§
Grout et al61 Quantitative, retrospective study 2932 13- to 18-year-old patientsk
Henrikson et al62 Qualitative, semistructured faceto-
face interviews and
telephone interviews
44 Physicians, NP, and PA
Hudson et al63 Qualitative, semistructured
interview
61 Immunization Nurses, FM, and
Pediatrics
Hyun et al13 Quantitative, cross-sectional Not stated Parents of adolescents{
Javaid et al64 Quantitative, cross-sectional 1132 Pediatrics, Nurse, FM, OBGYN,
and PA
Kasting et al65 Qualitative, semistructured
interviews
22 Physicians and NP with Pediatric
Specialty
Kulczycki et al66 Quantitative, cross-sectional 301 FM and Pediatrics
Malo et al67 Quantitative, cross-sectional 367 Pediatrics and FM
Perkins et al68 Qualitative, semistructured
interviews
33 Physicians, NP, and RN
Rosen et al69 Quantitative, cross-sectional 137 School nurses
Ylitalo et al72 Quantitative, cross-sectional 9274 Girls aged 13-17 years†
FM indicates family medicine; HPV, human papillomavirus; IM, internal medicine; NP, nurse practitioner; OBGYN, obstetrics-gynecology; PA, physician’s assistant; and RN, registered nurse.
†Study included female adolescent patients with provider-verified vaccination records.
*Study included girls aged 9 to 20 years of age enrolled in Medicaid for $6 months to identify claims for HPV vaccination along with individual, provider, and practice characteristics linked to vaccination.
‡Study included parents of adolescent children at 16 primary care practices to assess current provider communication practices and influence on HPV vaccine uptake.
§Study included parents of adolescents between the ages of 11 and 17 years of age assessing the quality of recommendations parents received for the HPV vaccine from health care providers.
kStudy included electronic medical records of 13- to 18-year-old patients to assess patient and provider characteristics associated with initiating the HPV vaccine.
{Study included parents of adolescents to assess vaccination rates, missed opportunities for vaccination, and role of health care provider recommendations in vaccine uptake.
S56 ROSEN ET AL ACADEMIC PEDIATRICS
CLINICIANS’ KNOWLEDGE AND BELIEFS ABOUT HPV AND
THE HPV VACCINE
Studies assessing clinicians’ knowledge of HPV and
HPV vaccine showed that knowledge varied widely. Correct
responses to items assessing HPV knowledge ranged
from 22% to 95%21,25,28,69 and correct responses to items
assessing HPV vaccine knowledge ranged from 17% to
91%.25,50,55,69 Clinicians’ knowledge level about HPV in
men was generally lower than their knowledge level for
women, and was particularly low with respect to
understanding of vaccine recommendations for men, such
as the upper age limit of the recommendation and which
male HPV-related cancers the vaccines prevents.39,49 In 1
study, knowledge level about the vaccine’s effectiveness
in preventing cervical cancer was higher than for
knowledge about the prevention of anal, oropharyngeal,
vulvar, and vaginal cancers.50 Clinicians also reported deficits
in knowledge about the risk of HPV infection in gay
and bisexual men.51 Clinicians generally believed that
HPV infection caused serious health complications (eg,
cervical cancer) and warranted a vaccine.37,55,70
CLINICIANS’ ATTITUDES AND BELIEFS ABOUT
RECOMMENDING HPV VACCINES
Clinicians’ attitudes and beliefs about recommending
HPV vaccines are summarized in Table 2. We identified 2
main themes: facilitating factors and barriers to recommending
HPV vaccines. Within each of these themes, study
findings were classified into the following subthemes:
personal, parent/patient-related, and systems-level facilitating
factors or barriers. Personal facilitating factors for
recommending HPV vaccines included personal beliefs
about vaccine benefits (eg, prevention of cancer,
22,28,33,42,47,49,50,59,63 prevention of HPV transmission,28
decreased health care costs,49 and benefits specific to
men28,49 and vaccine safety33,49,69). Parent and patientrelated
facilitating factors included cultural beliefs42 and vaccine
education for patients and families.38,42 Systems-level
facilitating factors included office procedures that reduce
missed opportunities to vaccinate,38 financial support for
vaccination (eg, the Vaccines for Children program),27 and
policies that promote vaccination.27,34 Barriers to
recommending HPV vaccines related to personal
knowledge and beliefs included insufficient knowledge
about HPV and HPV vaccines27 and a number of concerns
about HPV vaccines. Parent and patient-related barriers
included a lack of parental interest,26,38 lack of parental
understanding about the vaccines,21,31,38,64 and a number of
parental concerns that clinicians either anticipated or had
experienced. These included concerns about vaccine
safety,21,25,26,31,35,43,53,64,70 vaccine efficacy,21,25,43 negative
media reports,21 behavioral consequences of vaccination,
21,25,26,35 discussions about sexual topics,21,25,35,46,53
child being too young or not yet sexually
active,25,35,43,46,53,64 and vaccine cost.22,31 Systems-level
barriers included lack of clinic procedures to support
vaccination,26 insufficient vaccine supply,21,33 insufficient
reimbursement19,22,25–27,33,37,41,44,64 or insurance
coverage,21,23,25,49 and difficulty getting patients to return
for subsequent vaccine doses.25,35,38,43,64
CLINICIANS’ INTENTION TO RECOMMEND HPV VACCINES
Data summarizing clinicians’ intention to recommend
HPV vaccines, as well as factors associated with intention,
are shown in Table 3. In studies that examined intention
among clinicians, rates varied widely, from 16% to
96%.17,19–23,33,37,41,44,57,69,71 The mean for intention rates
was 66.9 (SD ¼ 23) and the median was 73; the 16%
intention rate was an outlier. In 2 studies that examined
intention according to patient age, intention was higher
for 13- to 18-year-olds (92%–96%) than 11- to 12-yearolds
(73%–78%).41,71 In a study on clinicians’ intention
to recommend the HPV vaccine according to patient
gender, 67% of clinicians intended to recommend HPV
vaccines only to female patients, whereas 14% intended
to recommend the vaccine to girls and boys equally.20 In
another study on implementation of the HPV vaccine for
boys, 62% of clinicians reported intending to recommend
the vaccine to boys.37 Intention to recommend to boys varied
according to age in 1 study, with the highest intention
rates (61%) reported for boys 13 to 17 years of age.21
Clinician-related factors included higher knowledge levels
about HPV,21 professional factors (eg, specialty20,23,57 and
national or professional society recommendations20), and
beliefs and attitudes about HPV vaccines (eg, beliefs about
vaccine safety and efficacy,22 about early vs late adoption
of new vaccines,17,33 and about behavioral effects of
vaccination56). Parent/patient-related factors associated
with intention included perception that the patient was at
high risk for HPV infection.44 Systems-level factors negatively
associated with intention included insufficient staff
time33 and lack of reimbursement for vaccination.33,44
CLINICIANS’ PROFESSIONAL PRACTICES REGARDING HPV
VACCINATION
Clinician’s professional practices regarding HPV vaccination
are summarized in Table 4. Themes identified were as
follows: 1) communication with parents/patients about
HPV vaccination, 2) clinician-reported vaccine recommendations
and factors associated with vaccine recommendations,
and 3) patient vaccination rates and factors
associated with vaccination rates. Studies on communication
with parents and patients about HPV vaccination addressed
various aspects of communication including strategies for
introducing the vaccine, population targeted for communication,
and consistency of recommendation. Recommendation
rates ranged from 34% to 93% across studies that reported
data not stratified according to age or
gender.14,21,25,26,28,32,33,39,43,45–47,50,52,54,60,70,72,73 In studies
on recommendation rates according to gender, rates for
girls ranged from 59% to 79%,43,54 and for boys ranged
from 7% to 84%.39,43,54,67 In studies on recommendation
rates according to age group, rates increased with age for
girls as well as boys: the highest reported rates were for
13- to 17- and 18- to 26-year-old girls21,28,47,59,72,73 and
boys.28,45,47,67 Several studies examined strength of HPV
ACADEMIC PEDIATRICS CLINICIANS’ KNOWLEDGE, ATTITUDES, AND PRACTICES REGARDING HPV VACCINATION S57
Table 2. Clinicians’ Attitudes and Beliefs About Recommending HPV Vaccines
Theme Results
Facilitating factors to recommending HPV vaccines
Personal beliefs
Vaccine benefits
Prevention of cancer22,28,33,42,47,49,50,59,63
Prevention of genital warts28
Prevention of transmission to and disease in future partners28
Decreased health care costs49
Better method of cervical cancer prevention than Papanicolaou test18
Vaccine benefits specific to young men
Prevents genital/anal warts49
Protect future partners from HPV infection and cervical cancer28,49
Herd immunity49
Vaccine safety33,49,69
Parent-/patient-related
Cultural beliefs
Latino families, immigrants more accepting42
Education of patients/families
Sheets exploring parental concerns, focus on cancer prevention42
Communication about clinic vaccine appointment protocol38
Systems-level
Office-level
Reducing missed opportunities through recall/reminder systems38
Financial support for vaccination (eg, VFC)27
Policies
State-level policies27,34
Mandated vaccination35,36,49,52
Barriers to recommending HPV vaccines
Personal knowledge and beliefs
Knowledge
Insufficient knowledge of HPV and HPV vaccines27
Beliefs and attitudes about HPV vaccines
Concerns about vaccine safety,25,27,56 efficacy,25,27,56 duration of immunity26,37
Low perceived risk of HPV-related diseases in one’s patients and belief HPV-related disease can be prevented in
other ways (eg, Papanicolaou screening)36
Perception that HPV vaccine is “less important” than other vaccines29,36
Hesitancy to recommend multiple vaccines at once36
Discomfort communicating about sexual topics36,51
Concerns about behavioral consequences of vaccination (sexual behaviors,65 decreased Papanicolaou
screening)19,27,33,53,69
Low perceived control over recommending22
Mistrust because of the emphasis on marketing of the vaccine in the media and by industry36
Beliefs and attitudes specific to young men: discomfort vaccinating young boys,49 lack of direct benefit/causes
too few cancers in men,28 genital/anal warts can be managed in other ways,28 too late to vaccinate if already
sexually active,28 no need to vaccinate men if women already being vaccinated28,64
Parent/patient-related
Lack of interest/parents not requesting26,38
Parental lack of education/understanding21,31,38,64
Belief that adolescents do not need vaccines35
Anticipated/experienced parental concerns
Vaccine safety/adverse effects,21,25,26,31,35,43,53,64,70 concern about “new” vaccine25,35,42,53
Lack of vaccine efficacy21,25,43
Concern that parent will think clinician is implying their child is sexually active49
Parental refusal because of negative media reports21
Parental request to delay vaccination41,46 (especially for patients 11–12 years old42)
Parental concerns about behavioral consequences of vaccination21,25,26,35
Parental mistrust of vaccines in general21,31
Parental reluctance for clinician to discuss sex, STI, or STI vaccine with their child21,25,35,46,53
Parental beliefs their child is not at risk42 (too young,25 not sexually active35,43,46,53,64)
Parental concerns about cost,22,31 HPV vaccine not covered by VFC35
Lack of a mandate leads parents to think HPV vaccine less important than other vaccines51
Systems-level
Clinic-related
Lack of staff to administer vaccines,26 lack of space to store vaccine,26 lack of system to track vaccines,26 lack of
vaccination records in Emergency Department44
(Continued)
S58 ROSEN ET AL ACADEMIC PEDIATRICS
vaccine recommendation, and to recommend the HPV
vaccine less strongly for younger versus older adolescents
and for boys versus girls.19,46,50,51,57,64 Some studies
showed that clinicians tend to recommend the HPV
vaccine as an “optional” vaccine, especially for 11- to
12-year-olds.29,46,62 Factors associated with higher
recommendation rates included clinician’s ethnicity (eg,
Latino clinicians were more likely to recommend vs those
with non-Latino ethnicity32,40,48), clinician professional
characteristics (eg, pediatricians more likely to recommend
vs other specialties27,32,46,57), higher level of clinician
knowledge about HPV vaccines,45,69 clinician attitudes and
beliefs about vaccination, patient-related factors (eg, girls
more likely to receive recommendation vs boys,28 older adolescents
more likely to receive recommendation vs younger
adolescents27), and systems-related factors (eg, higher
number of office procedures to maximize vaccination positive
associated21 and lack of reimbursement for vaccination
negatively associated45,52 with vaccination).
PATIENT HPV VACCINATION RATES
Several studies reported patient vaccination rates.
Specifically, 6 studies reported on vaccination rates on the
basis of review of medical records,24,40,54,61,72,74 and 5
Table 2. Continued
Theme Results
Insufficient vaccine supply21,33
Financial
Cost to provide vaccination/low reimbursement,19,22,25–27,33,37,41,44,64 lack of insurance coverage21,23,25,49
Insufficient time to recommend vaccine25,33,37,44,46,63
Competing priorities37
Multidose vaccine
Difficulty getting patients to return for subsequent doses25,35,38,43,64
HPV indicates human papillomavirus; STI, sexually transmitted infection; and VFC, Vaccines for Children program.
Table 3. Clinicians’ Intentions to Recommend HPV Vaccination
Theme Results
Intention rates
Overall range
16% to 96%17,19–23,33,37,41,44,57,69,71
Intention by patient age
11–12 years: 73%41 to 78%71
13–18 years: 92%71 to 96%41
Intention by patient gender
67% intended to recommend only to female patients20
14% intended to recommend to both boys and girls equally20
Overall intention to recommend to boys: 62%37
Boys 9–10 years: 22%21
Boys 11–12 years 42%21
Boys 13–17 years: 61%21
Boys 18–26 years: 60%21
Factors associated with intention to recommend
Clinician-related
Knowledge
Higher knowledge about HPV21
Professional factors
Specialty (pediatricians more likely to report intention to recommend vs other specialties)20,23,57
National recommendations (Food and Drug Administration20) and professional society recommendations20
Clear recommendation guidelines66
Beliefs and attitudes
Beliefs that vaccines are safe and effective22
Being an early adopter versus late adopter17,33
Anticipating parental concerns17
Belief that vaccination would increase riskier behaviors (negative association)56
Belief that vaccines should be mandated21
Subjective norms (ie, willingness to adhere to the Advisory Committee on Immunization Practices
recommendations, and perceived people they thought were important expected them to vaccinate patients)
and perceived behavioral control (ie, if the clinician believed it was within their control to vaccinate the
patient)22
Parent/patient-related
Perceived patient to be at high risk44
Systems-level
Insufficient staff time (negative association)33
Lack of reimbursement (negative association),33,44 cost (negative association)22
Lack of time to discuss HPV vaccine during visit (negative association)44
HPV indicates human papillomavirus.
ACADEMIC PEDIATRICS CLINICIANS’ KNOWLEDGE, ATTITUDES, AND PRACTICES REGARDING HPV VACCINATION S59
Table 4. Clinicians’ Professional Practices Regarding HPV Vaccination
Theme Results
Communication with parents and patients about HPV vaccination
Content of communication
Emphasis on cancer prevention over STI/genital wart prevention19,25,30,35,49,51,67
Personal protection was emphasized more than protection of partners25,67
Importance of vaccination before sexual initiation29,50,53,67
Provide materials developed by the Centers for Disease Control and Prevention, vaccine
manufacturer, the Immunization Partnership, American Cancer Society46,49,51,64,69
Strategies for introducing vaccine
Saying child is due for HPV vaccination29,51
Suggesting child get HPV vaccine51,64
Tend to recommend other vaccines (eg, Tdap) first, HPV vaccine last29,51,52,64
Population targeted for communication
Recommend to girls more frequently than boys51
More likely to recommend in older versus younger patients19,25,50,57,62,64
Consistency of recommendation
Less likely to recommend vaccines at sick versus well visits (if recommended at sick visits, less likely
to recommend HPV compared with other vaccines)22,51,52,58
Communication if parent deferred initiation at a previous visit: some clinicians not likely to
recommend at future visit29,46,57
Sources of information about HPV vaccine
Professional organizations, scientific literature, professional conferences/meetings, academic
lectures/grand rounds (less commonly cited: colleagues, media, industry)21
Clinician-reported vaccine recommendations
Recommendation rates
Overall recommendation rates
Range: 34% to 93%14,21,25,26,28,32,33,39,43,45–47,50,52,54,60,70,72,73
Recommendation according to patient age
9–10 years: 13%25
11–12 years: 56%–73%25,52
13–15 years: 90%25
16–18 years: 94%25
19–26 years: 94%25
Recommendation according to patient gender
Girls
All age groups: 59%–79%43,54
9–10 years: 18%–68%21,28,47,73
11–12 years: 49%–76%21,28,46,47,59,73
13–17 years: 60%–98%21,28,47,59,72,73
18–26 years: 57%–98%21,28,47,59
Boys
All age groups: 7%–84%39,43,54,67
9–10 years: 9%–24%28,47,67
11–12 years: 11%–64%28,45,47,67
13–17 years: 13%–93%28,45,47,67
18–26 years: 13%–93%28,45,47,67
Type/strength of recommendation
Recommendations lack in consistency (recommending routinely vs risk-based approach) and
urgency (recommending same-day vaccination)51
Strength of recommendation compared with other vaccines and for specific age groups and genders
Recommend HPV vaccine as an “optional” vaccine,67 especially for 11- to 12-year-old
adolescents29,46,62
Recommend HPV vaccine less strongly than for other vaccines, recommend less strongly for
younger versus older age groups and boys versus girls19,46,50,51,57,64
More likely to “highly endorse” other vaccines versus HPV vaccines for 11- to 12-year old
adolescents,51,67 studies of parents support these findings (ie, HPV vaccine reported by
parents as less strongly recommended than other adolescent vaccines)14,51
Strength of recommendation according to specialty
Pediatricians more likely to strongly recommend than family physicians27,40,46,50,57,74
Trends in recommendation
Increasing recommendations over time since vaccines were licensed for early adolescents (11–12
years old)48
Factors associated with vaccine recommendations
Clinician personal characteristics
Ethnicity/race: Latino clinicians more likely to recommend versus non-Latino, nonwhite versus
white32,40,48
Vaccines for Children provider40,72
(Continued)
S60 ROSEN ET AL ACADEMIC PEDIATRICS
Table 4. Continued
Theme Results
Clinician professional characteristics
Pediatrician more likely to recommend versus other specialties27,32,46,57
Clinician knowledge
Higher knowledge of HPV45,69
Ambivalence about the clarity of HPV vaccination guidelines (negative association)66
Clinician attitudes and beliefs
Facilitating factors
Higher intention to recommend46
Being an early adopter19,45
Belief that vaccines are effective and safe19,70
Perceived risk among their patient population62
Belief that immunity is long-lasting19,70
Perception that professional organizations are valuable sources of information21
Belief in mandated vaccination21
Lower (in one study, higher) number of barriers to recommendation experienced21
Barriers
Concern about vaccine efficacy19
Concern about waning immunity70
Personal belief that the vaccine not necessary because patient is not at risk because not yet
sexually active or too young62
Discomfort discussing STIs with parents, perception that having to talk about an STI will make
conversations about the HPV vaccine uncomfortable25
Concerns about riskier sexual behaviors after vaccination70
Insufficient time to discuss HPV or vaccine25,29
Perceived/experienced parent-related barriers: belief that parents believe the vaccine is not
important,35 expectation that parent will refuse,29 parental concerns about vaccine safety and
efficacy,29 parental belief that girls should be the ones to take preventive measures,64 parents
deferring vaccination when offered,25,29,57 parents believe vaccine will promote sexual
activity35
Patient-related factors
Demographic-related
Boys receiving fewer recommendations versus girls28
Older adolescents more likely to receive recommendation versus younger27
Race (inconsistent associations): non-Hispanic white versus non-Hispanic black, higher Latino
population, non-Hispanic black versus other35,40,57,72
Insurance status
Higher proportion of Medicaid/nonprivate insurance patients25,45,72
Lower rates of uninsured72
Systems-related factors
Higher number of office procedures that maximize vaccination21
Lack of reimbursement for vaccination (negative association)45,52
Lack of time to discuss vaccine during the office visit (negative association)25,29
Vaccines for Children program provider45,72
Patient vaccination rates
Overall vaccination rates
Range: 24%–62%24,40,54,72,74
Vaccination rates according to age:
11–12: 28%24
13–15: 28%24–76%61
16–18: 24%24–78%61
Vaccination rates according to patient gender:
Girls: 35%–84%13,54,61,72,74
Boys: 44%13–65%61
Factors associated with patient vaccination rates
Clinician personal characteristics
Demographic-related factors
Physician gender (men less likely to report that most of patients were vaccinated)41
Clinician knowledge
Higher knowledge about vaccine31
Centers for Disease Control and Prevention/professional society guidelines31
Clinician professional characteristics
Specialty (vaccination rates higher among pediatricians vs other)27,61,74
Practice characteristics
Private practice more likely to have higher vaccination rates versus ambulatory care/urgent care/
community health clinic74
Residency training on vaccine use31
Science is the pursuit and application of knowledge and understanding of the natural and social…
Clearly stating the definition, the values, the meaning of such values and the type of…
All answered must be typed using Times New Roman (size 12, double-spaced) font. No pictures…
All answered must be typed using Times New Roman (size 12, double-spaced) font. No pictures…
https://www.npr.org/sections/ed/2018/04/25/605092520/high-paying-trade-jobs-sit-empty-while-high-school-grads-line-up-for-university Click on the link above. Read the entire link and answer the questions below…
All answered must be typed using Times New Roman (size 12, double-spaced) font. No pictures…